Rajeev K Pathak

Has grant

Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Electrophysiologic Phenotyping of Non ischaemic Cardiomyopathy to Predict Clinical Outcome

Open Date: 2016-01-01

Close Date: 2019-01-01

Articles (8)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Aims Heart failure patients with mid‐range ejection fraction (HFmrEF) have overlapping clinical features, compared with patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). We aim to perform a meta‐analysis of studies reporting long‐term outcomes in HFmrEF compared with HFrEF and HFpEF. Methods and results Data from 18 eligible large‐scale studies including 126 239 patients were pooled. Patients with HFmrEF had a lower risk of all‐cause death than those with HFrEF [risk ratio (RR) = 0.92; 95% CI = 0.85–0.98; P < 0.001]. This significant difference was seen in the follow‐up at 1, 2, and 3 years. Patients with HFmrEF had significantly lower risk of cardiovascular (CV) deaths than HFrEF (RR = 0.77; 95% CI = 0.65–0.92; P < 0.001). Subgroup analysis showed that studies recruiting >50% of males had higher risk of deaths with HFrEF (RR = 1.15; 95% CI = 1.04–1.26; P = 0.006). When compared with HFpEF, patients with HFmrEF had comparable risk of all‐cause death (RR = 1.02; 95% CI = 0.96–1.09; P = 0.53). Similarly, there were no differences in the 1, 2, and 3 year deaths; CV and non‐CV deaths were insignificant between HFmrEF and HFpEF. Conclusions The results of the study support that HFmrEF has better prognosis than HFrEF but similar prognosis when compared with HFpEF. Gender disparity between studies seems to influence the results between HFmrEF and HFrEF. Transition in left ventricular ejection fraction (LVEF), which could not be addressed in the study, may play a decisive role in determining outcomes. PROSPERO review registration number CRD42021277107.

Year:

2022

Collaborators (7)

Melissa Middeldorp

University of Groningen

NETHERLANDS
View details

Daniele Muser

Assistant Professor of Medicine

Humanitas University

ITALY
View details

Frederic Anselme

Professor in cardiology

University of Rouen

FRANCE
View details

Martin Stiles

University of Auckland

NEW ZEALAND
View details

Anand N Ganesan

-

AUSTRALIA
View details

Eliot Peyster

University of Pennsylvania

UNITED STATES
View details

Prashanthan Sanders

Group Leader, Centre for Heart Rhythm Disorders

South Australian Health and Medical Research Institute

AUSTRALIA
View details